Moderna (NASDAQ:MRNA) Announces Earnings Results

Key Points

• Moderna reported quarterly earnings of ($2.13) EPS, exceeding expectations of ($2.99) and generating revenue of $142 million, which was above the forecast of $116.26 million.
• The company's stock has a current price of $27.60 and a market capitalization of $10.67 billion, with analysts giving it a consensus rating of "Hold" and a target price of $46.11.
• Institutional investors own approximately 75.33% of Moderna's stock, with significant increases in holdings noted by NewEdge Advisors and other firms during the first quarter.

Moderna (NASDAQ:MRNA - Get Free Report) issued its earnings results on Friday. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86, Zacks reports. The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna's revenue was down 41.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($3.33) earnings per share. Moderna updated its FY 2025 guidance to EPS.

Moderna Price Performance

Shares of MRNA traded up $0.01 during trading hours on Tuesday, hitting $27.65. The company's stock had a trading volume of 1,844,549 shares, compared to its average volume of 10,881,933. The company has a market cap of $10.69 billion, a price-to-earnings ratio of -3.67 and a beta of 1.83. The business has a 50 day simple moving average of $29.22 and a two-hundred day simple moving average of $30.24. Moderna has a 52-week low of $23.15 and a 52-week high of $91.99.

Hedge Funds Weigh In On Moderna

Several large investors have recently modified their holdings of MRNA. AQR Capital Management LLC purchased a new position in shares of Moderna in the first quarter worth about $415,000. NewEdge Advisors LLC boosted its position in shares of Moderna by 732.7% in the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company's stock valued at $328,000 after acquiring an additional 10,185 shares during the period. Focus Partners Wealth boosted its position in shares of Moderna by 58.7% in the first quarter. Focus Partners Wealth now owns 23,547 shares of the company's stock valued at $668,000 after acquiring an additional 8,706 shares during the period. Finally, United Services Automobile Association bought a new position in shares of Moderna in the first quarter valued at approximately $230,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRNA. William Blair reissued a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Citigroup began coverage on shares of Moderna in a research note on Friday. They set a "neutral" rating and a $40.00 target price on the stock. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. Barclays cut their target price on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research note on Monday. Finally, Morgan Stanley reissued an "equal weight" rating and set a $32.00 target price on shares of Moderna in a research note on Friday. Four investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $45.61.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.